Skip to content

Contract award

Source: Physiomics News
Share
Copied link to clipboard!

Physiomics plc (AIM: PYC), the consultancy using mathematical models to support the development of drug treatment regimens and personalised medicine solutions, is pleased to announce that it has been awarded a contract by new client, Ankyra Therapeutics (“Ankyra”). Ankyra is a Boston-based biotech focused on improving both the safety and efficacy of cancer treatment by using their proprietary anchored immunotherapy platform. Ankyra recently announced a successful US$45 million Series B funding round to finance its lead molecule, ANK-101, through Phase 1 clinical trials and has an emerging pipeline of additional immunotherapy-based programs.  Physiomics will be supporting Ankyra with modelling and simulation of ANK-101 in immune-oncology settings in support of its early development.

Physiomics CEO, Dr Jim Millen, commented: “We are delighted to have been selected by Ankyra Therapeutics as its partner for this modelling and simulation project focused on exciting new molecule ANK-101 and look forward to working with its talented team.